Choice of Valve Substitute in the Era of Oral Anticoagulation Self-Management

The optimal valve substitute for patients between 60-70 years is controversial. We compared anticoagulation-related adverse events (ARAE) in patients receiving mechanical heart valve replacement (MHVR) on INR self-management vs. stentless bioprosthesis, to assess whether the risk of structural valve deterioration (SVD) is still out-weighted by the benefit of not requiring permanent anticoagulation.

Inclusion Criteria:

• heart valve replacement

Exclusion Criteria:

• CABG
• Afib